Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Immuneering announced that updated survival data from a Phase 2a trial of atebimetinib plus mGnP in first-line pancreatic cancer will be presented in an oral session at the 2026 ASCO Annual Meeting. The presentation will feature an expanded cohort of 55 patients, which includes the initial 34 patients previously reported plus an additional 21.
Key figures
- Drug Name
- atebimetinib (IMM-1-104)
- Phase Of Trial
- Phase 2a
- Total patients
- 55
- Abstract number
- 4013
- Previous cohort
- 34
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.